Alector Licenses Brain Enzyme Program to Genentech for $100 Million Upfront

What happened

Alector, Inc., a South San Francisco company that develops therapies for neurodegenerative diseases, disclosed in a Form 8-K filed October 5, 2026 that it entered a license agreement with Genentech, Inc. on September 30, 2026. Under the agreement, Alector grants Genentech exclusive worldwide rights to develop and commercialize its AL050 program, described in the filing as a brain-penetrant engineered glucocerebrosidase (GCase) enzyme replacement therapy.

Alector will receive a $100 million upfront payment, according to the filing, and is eligible for up to an additional $1.17 billion in development, regulatory, and commercial milestone payments tied to the GCase candidates. The company would also receive tiered royalties on a specified percentage of net sales, at rates the filing describes as ranging from single-digit to double-digit percentages. Genentech takes over development, regulatory, manufacturing, and commercialization responsibilities, and Alector will assign certain patents specific to the GCase candidates to Genentech. Alector keeps ownership of its Alector Brain Carrier platform and rights to use it across its wholly owned pipeline outside of GCases.

In a related move on the same date, Alector exercised its option to license certain patents from Spur Therapeutics Limited under an option and license agreement dated August 14, 2026. Alector had already paid Spur a $500,000 upfront option payment; following the option exercise and receipt of the Genentech upfront payment, Alector will pay Spur $15 million plus a percentage in the teens of milestone and other non-royalty partnering income from sublicensing the Spur patents, and additional royalties calculated as a percentage of royalties Alector receives from such sublicenses.

The filing also gives a preliminary cash figure. Alector estimated cash, cash equivalents, and marketable securities of approximately $138.7 million as of September 30, 2026. Giving pro forma effect to the initial Genentech payment received and the Spur payment made, that figure would have been approximately $223.7 million, which the company said it believes will fund operations into 2029. Alector noted the quarter-end close process was not complete, that the estimate is preliminary and unaudited, and that its auditors have not reviewed it.

Market reaction

The stock closed at $1.99 on the event date, a 9.94% change from the prior close of $1.81, according to the price data. Volume was 88,911,449 shares against an average volume of 1,208,738 — roughly 73.6 times the usual level.

What this means

A Form 8-K is the current report a US public company files to disclose material events between its quarterly and annual reports. It is not a periodic earnings report; it is triggered by specific events, and the company ticks the applicable item boxes on the cover. This filing carried five: Item 1.01 (entry into a material definitive agreement), Item 2.02 (results of operations and financial condition), Item 7.01 (Regulation FD disclosure), Item 8.01 (other events), and Item 9.01 (financial statements and exhibits).

Item 1.01 is the one that matters most here, because it is where the Genentech and Spur agreements are described. Licensing a drug program is a common way for a small biotech to bring in cash without selling stock or debt: the larger partner takes on the cost and risk of later-stage development and commercialization, and the smaller company receives an upfront payment plus contingent payments if the program hits milestones or sells.

Those contingent numbers need careful reading. The $100 million upfront is a definite payment. The $1.17 billion figure is the maximum total of milestone payments Alector could receive if all specified development, regulatory, and commercial goals are met — it is a ceiling, not an amount received, and the filing does not state a schedule, probability, or timeline for those milestones. Royalties are likewise contingent on actual net sales, and the rates are given only as a range from single-digit to double-digit percentages, with the exact tiers redacted.

The underlying asset is an enzyme replacement therapy. GCase, or glucocerebrosidase, is an enzyme; in some neurodegenerative conditions it is thought that reduced GCase activity contributes to disease. Enzyme replacement therapy means supplying a working version of the enzyme rather than a small-molecule drug. "Brain-penetrant" means the version Alector engineered is intended to cross the blood-brain barrier, the selective boundary that keeps most large molecules out of the brain. Alector's platform, the Alector Brain Carrier, is the technology it uses to shuttle compounds across that barrier; under the deal it retains that platform and the right to apply it outside GCase programs.

Item 2.02 is where companies release earnings or, as here, preliminary financial figures. Alector did not report revenue or loss — it disclosed a cash balance only, and labeled it an estimate because the quarter had just ended and the books were not closed. The pro forma column is the instructive part: pro forma means "as if these transactions had already occurred." Alector separated the $138.7 million it actually held on September 30 from the roughly $223.7 million it would have held had the Genentech upfront been received and the Spur payment been made by that date. The difference of about $85 million is consistent with a $100 million receipt less the $15 million Spur payment, though the filing does not do that arithmetic for readers.

Regulation FD, cited as Item 7.01, stands for "fair disclosure." It requires that when a company gives material nonpublic information to certain outside parties, it must also make that information public — here through the attached press release, Exhibit 99.1. The filing states that the Item 7.01 information is not "filed" for purposes of Section 18 of the Exchange Act, a standard carve-out meaning the company does not assume the added liability that attaches to formally filed disclosure.

The filing does not state why Alector chose to license AL050 to Genentech rather than develop it further alone, and no reason should be inferred beyond the terms described. What the document does establish is the structure: Alector hands off development and manufacturing of the GCase candidates, keeps its platform, and receives a defined upfront payment plus contingent future payments, with a cash runway it says extends into 2029. The full agreements are to be filed as exhibits to a later periodic report, with confidential portions redacted.